Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06910553 · ClinicalTrials.gov registry record
IBD Pregnancy Registry
A clinical trial of Inflammatory Bowel Disease (IBD), sponsored by CorEvitas.
- Recruiting
- Registry status
- 832
- Enrollment target
- 1
- Study location
NCT06910553: Recruiting study of Inflammatory Bowel Disease (IBD), sponsored by CorEvitas.
NCT06910553 is a study of Inflammatory Bowel Disease (IBD) that is actively recruiting participants, run by CorEvitas. The registered enrollment target is 832 participants, above the 205-participant average among 12 other Inflammatory Bowel Disease (IBD) trials with a reported enrollment target (306% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06910553, a study of Inflammatory Bowel Disease (IBD), is actively recruiting participants, sponsored by CorEvitas.
- RECRUITING
- Registry status
- 832 participants
- Enrollment target
- 1
- Study location
Study Summary
Data collected through the registry may be used to address a range of research questions and objectives, including but not limited to the following: Research question: Is there an increased risk of adverse maternal, fetal, or infant outcomes among individuals who are exposed to Inflammatory Bowel Disease (IBD) treatments during pregnancy? The primary objective of the registry is to estimate the prevalence of major congenital malformations among pregnant individuals with IBD who are exposed to an IBD pharmacotherapy during pregnancy. The secondary objectives of the registry are: To estimate the prevalence of other maternal, fetal, and infant outcomes among pregnant individuals with IBD who are exposed to IBD pharmacotherapies during pregnancy. To contextualize the prevalence of outcomes among pregnant individuals who are exposed to IBD pharmacotherapies during pregnancy and estimate the prevalence of all outcomes of interest among pregnant individuals with IBD who are not exposed to any IBD pharmacotherapies or an IBD pharmacotherapy of interest during pregnancy. If sample size permits, to estimate the risk ratio for each outcome, comparing the outcomes of pregnant individuals with IBD who are exposed to IBD pharmacotherapy with those who are not exposed to any IBD pharmacotherapies or an IBD pharmacotherapy of interest during pregnancy. Data collection may be used to determine pharmacotherapy-specific use with or without unexposed cohorts on an as-needed basis, as sample size allows.
Primary Outcome
An abnormality of body structure or function that is present at birth, is of prenatal origin (i.e., birth defect), has significant medical, social, or cosmetic consequences for the affected individual, and typically requires medical intervention.
Conditions Studied
Interventions
- OTHER Non-exposed group
- DRUG Exposed to IBD pharmacotherapy during pregnancy
Study Locations (1)
North Carolina
- PPD - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 832 participants |
| Start Date | 2025-04 |
| Est. Completion | 2032-09 |
What NCT06910553 shows while recruiting
NCT06910553 is an observational study that tracks outcomes without assigning an intervention. The registered 832 participants enrollment target is mid-sized for trials with a published cap, above the 205-participant average among 12 other Inflammatory Bowel Disease (IBD) trials with a reported enrollment target (306% higher).
The record links to 1 condition, with Inflammatory Bowel Disease (IBD) appearing as the primary indexed condition, and to 2 interventions - of which Non-exposed group is the first listed.
NCT06910553 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06910553 about?
NCT06910553 is a clinical study titled "IBD Pregnancy Registry". Data collected through the registry may be used to address a range of research questions and objectives, including but not limited to the following: Research question: Is there an increased risk of adverse maternal, fetal, or infant outcomes among individuals who are exposed to Inflammatory Bowel D...
What is the current status of trial NCT06910553?
This trial is currently recruiting. The enrollment target is 832 participants. The study started on 2025-04. Estimated completion is 2032-09.
What conditions does trial NCT06910553 study?
This clinical trial studies the following conditions: Inflammatory Bowel Disease (IBD).
What interventions are being tested in trial NCT06910553?
The interventions under investigation include: Non-exposed group (OTHER), Exposed to IBD pharmacotherapy during pregnancy (DRUG).
Who is sponsoring clinical trial NCT06910553?
This trial is sponsored by CorEvitas, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06910553 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammatory Bowel Disease (IBD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06910553's enrollment target sits among peer trials
832 2nd of 12 the highest of 12 other Inflammatory Bowel Disease (IBD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammatory Bowel Disease (IBD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
RECRUITING
-
Study of DISC-0974-201 in Participants With IBD and Anemia
RECRUITING · Phase 2
-
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
RECRUITING
-
Evaluation of the SMART IBD App in Pediatric IBD
RECRUITING · NA
-
Family Members At INcreased-risk for Developing Inflammatory Bowel Disease
RECRUITING
-
Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07089706 · 832 participants · Phase 4
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
- NCT05067283 · 830 participants · Phase 1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- NCT06592924 · 830 participants · Phase 3
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- NCT06868277 · 830 participants · Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia